Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England

References

• World Health Organization (WHO). Chronic obstructive pulmonary disease (COPD); 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)#:~:text=Chronic%20obstructive%20pulmonary%20disease%20(COPD)%20is%20the%20third%20leading%20cause,%2Dincome%20countries%20(LMIC). Accessed May 2, 2022.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2021 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2021. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed April 1, 2021.
   Google Scholar
• Sansbury LB, Bains C, Lipson DA, Ismaila AS, Landis SH. Real-world treatment patterns of multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in UK general practice. Int J Chron Obstruct Pulmon Dis. 2021;16:1255–1264. doi:10.2147/COPD.S290773
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Trelegy Ellipta EPAR summary of product characteristics; 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/trelegy-Ellipta-epar-product-information_en.pdf. Accessed April 1, 2021.
   Google Scholar
• Electronic Medicines Compendium. Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution; 2017. Available from: https://www.medicines.org.uk/emc/medicine/33828#gref. Accessed April 1, 2021.
   Google Scholar
• Electronic Medicines Compendium. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension; 2020. Available from: https://www.medicines.org.uk/emc/product/12028/smpc. Accessed April 1, 2021.
   Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• van der Palen J, Thomas M, Chrystyn H, et al. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med. 2016;26:16079. doi:10.1038/npjpcrm.2016.79
   PubMed Web of Science ®Google Scholar
• Svedsater H, Dale P, Garrill K, Walker R, Woepse MW. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13(1):72. doi:10.1186/1471-2466-13-72
   PubMed Web of Science ®Google Scholar
• Halpin DM, Worsley S, Ismaila AS, et al. INTREPID: single-versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–2020. doi:10.1183/23120541.00950-2020
   PubMedGoogle Scholar
• Wu B, Mu G, Bogart M. Characteristics of new users of fluticasone furoate/umeclidinium/vilanterol or multiple-inhaler triple therapy in patients with chronic obstructive pulmonary disease. AMCP eLearning Day; 2020. Available from: https://plan.core-apps.com/amcp2020/abstract/a952fc2ad5de2fbd1164d14c6bd0e2ec. Accessed May 23, 2022.
   Google Scholar
• Rothnie KJ, Joksaite S, Ismaila AS, Sansbury LB. Characteristics of new users of single and multiple-inhaler triple therapy for COPD in primary care in England. Eur Respir J. 2020;56(suppl 64):2417. doi:10.1183/13993003.congress-2020.2417
   Web of Science ®Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740–1740g. doi:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar
• NHS Digital. Hospital Episode Statistics (HES); 2020. Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics. Accessed April 1, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2019 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2019. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed April 1, 2021.
   Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS One. 2016;11(3):e0151357. doi:10.1371/journal.pone.0151357
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771–782. doi:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X
   PubMed Web of Science ®Google Scholar
• Sansbury LB, Rothnie KJ, Bains C, Compton C, Angley G, Ismaila AS. Healthcare, medication utilization and outcomes of patients with COPD by GOLD classification in England. Int J Chron Obstruct Pulmon Dis. 2021;16:2591–2604. doi:10.2147/COPD.S318969
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med. 2018;142:73–80. doi:10.1016/j.rmed.2018.07.009
   PubMed Web of Science ®Google Scholar
• Tinkelman DG, Price DB, Nordyke RJ, Halbert R. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75–80. doi:10.1080/02770900500448738
   PubMed Web of Science ®Google Scholar